Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2147)

[derogher]

Novavax (NVAX) filed a prospectus to sell up to $250 million of shares of common stock as it prepares to scale up production of its coronavirus vaccine candidate.

Shares in Novavax jumped 31% to close at $56.96 in U.S. trading on Monday after their value more than doubled over the past month.

The late-stage biotech company, which is in the process of developing a coronavirus antigen vaccine candidate, said that the net proceeds from the sale of common stock will depend on the number of shares actually sold and the offering price for such shares. The company based its calculation on the event that all of the offered shares would be sold at $43.63, the closing price per share on May 15.

“We intend to use the net proceeds from this offering for general corporate purposes, including but not limited to working capital, capital expenditures, research and development expenditures, clinical trial expenditures, as well as acquisitions and other strategic purposes,” Novavax said in the prospectus filing.

The offering comes after Novavax announced last week that it will receive $384 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop and produce its coronavirus vaccine candidate. The biotech company has set itself the aim of producing up to 100 million vaccine doses by end of 2020. For 2021, it is planning to target large-scale manufacturing capacity in multiple countries with a goal of potentially producing over one billion doses during the year.

Five-star analyst Mayank Mamtani at B. Riley FBR on Monday raised his price target on the biotech stock to $53 a share from $43 and kept his Buy rating, following a meeting with Novavax management to review progress on on its COVID-19 vaccine development.

“We believe NVAX not only offers a clinically validated adjuvanted recombinant nanoparticle platform (recently reporting overwhelmingly positive data in the Ph. III NanoFlu) but, also, demonstrates the ability to illicit a potent immune response at extremely low doses, boding favorably for both safety and scalability, with management guiding to 100M doses by YE20 and >1B during 2021,” Mamtani wrote in a note to investors. “With a regulatory path becoming relatively clearer, likely on the basis of Ph. IIb results by leveraging Emergency Use Authorization (EUA), we increase the probability of success, from 25% to 40%, which drives our PT increase.”

The rest of Wall Street analysts covering the stock in the past three months join Mamtani in their recommendation to Buy the shares adding up to a Strong Buy consensus. Following the stock’s rally, the $47.60 average price target indicates 16% downside potential in the coming 12 months.

https://finance.yahoo.com/news/novavax-seeks-raise-250-milli…

[marc2512]

Und was gibts Neues? Keine news?
Aussicht heute?

Gruss

[pickuru]

Gregory Glenn von "Novavax" im Interview vom 14. Mai 2020

https://aktien-boersen.blogspot.com/2020/05/gregory-glenn-vo…

[E-Jack-cool_at]

Ob hier demnächst eine Kapitalerhöhung ansteht? Das war ja schon längere Zeit im Gespräch, und soweit ich weiß sind auch in den ganzen Jahren seit 1988 etliche durchgeführt worden. Der jetzige Kurs wäre für das Management verlockend. Für die weitere Arbeit (außerhalb Corona) wird unbedingt Geld benötigt. Die 388 Millionen werden bestimmt restriktiv an bestimmte Maßnahmen hinsichtlich des Sars-Cov2 Virus gebunden sein. Und das Geld kommt auch nicht in einer Tranche. Außerdem ist es eine Maximalzusage seitens CEPI.
Für das eigentliche wichtige Produkt NanoFlu können diese Mittel nicht verwendet werden. Es sind aber erhebliche Mittel für Zulassung, Ausbau der Produktionskapazitäten, Vertrieb und Vermarktung notwendig.
Vor der CEPI -Zusage war der Kurs bei um 18, und es wurde bei einer KE mit einem Rückgang auf 15 gerechnet.

[DasTier666]

nur zur Erinnerung

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

GAITHERSBURG, Md., March 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII) today announced a commercial license agreement for the use of Novavax’ proprietary Matrix-M™ vaccine adjuvant with SII’s malaria vaccine candidate. SII licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum-induced malaria disease, from the Jenner Institute at Oxford University in 2017. Matrix-M is a key component in the malaria vaccine candidate, currently in a Phase 2b clinical trial sponsored by the Jenner Institute, with top-line data expected to be reported in the second quarter of 2020.
...
In addition, as part of the arrangement, Novavax has gained the rights to sell and distribute the SII-manufactured vaccine in high-income countries, primarily in the travelers and military vaccine markets.
...
“Novavax’ next-generation adjuvant, Matrix-M, is an impressive and critical component in this much-needed malaria vaccine,” said Adar Poonawalla, Chief Executive Officer of Serum Institute of India. “This will be an important long-term partnership in advancing an innovative potential malaria vaccine and while we have much work to do, this marks a key step forward.”
...
Globally, the World Health Organization estimated that in 2018, over 200 million clinical cases of malaria occurred, resulting in over 400,000 deaths, mostly children in Africa.1 Globally, malaria is the one of the leading causes of death in children younger than age five years.

http://ir.novavax.com/news-releases/news-release-details/nov…
https://www.who.int/publications-detail/world-malaria-report…

[Trailblaze]

Great US article on Novavax https://youth-investment-group.com/2020/05/12/novavax-set-to…

[kgunther]

Antwort auf Beitrag Nr.: 63.665.257 von marc2512 am 13.05.20 17:10:55

Geht schon noch

Zitat von marc2512:

Zitat von boss3: lohnt sich der einstieg jetzt noch

Du kannst reingehen und ein Stop setzen, das Du regelmäßig anpaßt.
Ich bin seit 18$ drin und habe gut drei %des Depotwertes investiert.

[marc2512]

Antwort auf Beitrag Nr.: 63.664.825 von boss3 am 13.05.20 16:47:39

Zitat von boss3: lohnt sich der einstieg jetzt noch

Schwer zu sagen. Kommt drauf an was du willst / erwartest. x10 wird schwierig. +20% - +80% können sicher noch drin sein wenn alles passt evtl. auch mehr. Allerdings kanns halt auch 📉 gehen.
Würde mich auf long einstellen wenn ich jetzt reingeh.

Bin seit 11 EUR drin.

[boss3]

Antwort auf Beitrag Nr.: 63.663.604 von marc2512 am 13.05.20 15:45:57

lohnt sich der einstieg jetzt noch

[marc2512]

Endlich wieder grün heute :-) Hab schon gedacht ich hab den Ausstieg verpasst